Flavokawain B is primarily studied for its potential anticancer properties. It has shown activity against various cancer cell lines, including breast, prostate, liver, and colon cancers, by inducing apoptosis and inhibiting cell cycle progression. Research indicates it may suppress tumor growth by modulating signaling pathways such as NF-κB, PI3K/Akt, and MAPK. It also exhibits anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and inhibiting enzymes involved in inflammation. Additionally, Flavokawain B has been investigated for its antioxidant properties, helping to neutralize free radicals and reduce oxidative stress. Due to these biological activities, it is considered a candidate for developing nutraceuticals and adjuvant cancer therapies, though clinical evidence remains limited and further studies are needed to establish efficacy and safety in humans.